Nootropics Powder Donepezil for Alzheimer’s Disease

Molecular Formula:C24H29NO3
Formula Weight:379.49
CAS No.:120014-06-4
Purity:99%
Appearance:white powder

Donepezil Base
 
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the palliative treatment of Alzheimer’s disease. Common side effects include gastrointestinal upset. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a biological half-life of about 70 hours, it can be taken once a day.

Donepezil has been tested in other cognitive disorders (and is sometimes used off label) including Lewy body dementia and vascular dementia, but it is not currently approved for these indications. Donepezil has been found to improve sleep apnea in Alzheimer’s patients. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, CADASIL, and Down syndrome.

A 3 year NIH trial in patients with mild cognitive impairment reported that donepezil was superior to placebo in delaying rate of progression to dementia during the initial 18 months of the study but this was not sustained at 36 months. In a secondary analysis, a subgroup of individuals with the Apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study. However at this time donepezil is not indicated for prevention of dementia. Recent studies suggest that Donepezil can improve speech in children with autism. The studies found that speech of autistic children who were mild to moderately affected appeared to improve from the use of Donepezil.

The COA:

TEST ITEM  SPECIFICATION RESULT
Appearance Off white to white crystalline powder Complies
Solubility freely  Freely soluble in chloroform, soluble
 in water and Acetic acid, slightly soluble in
 Acetonitrile  and ethanol, insoluble in
 Ethylacetoacetate and  n-hexane
Complies
Identification (1)By IR absorption ,To match with working
 standard
Complies
(2) The retention time of the major peak of
 the sample should  accord with that of the
 working standard.
Complies
 
(3) Test for chlorides. Reponds to the test
 for Chlorides.
Complies
 
PH  4.0-7.0 6.10
Residue on ignition ≤0.1% 0.03%
Related substance  Any Unkonwn single impurity≤0.3%
Total ≤0.5%
0.04% 
0.18%
Heavy metal   ≤10ppm <10ppm
Residual Solvents Methanol≤0.3%
Ethanol≤0.5%
Ethyl acetate≤0.5%
Toluene≤0.089%
Acetic acid≤0.5%
Not detected
Not detected
Not detected
Not detected
Not detected
Loss on drying ≤0.5% 0.20%
Assay On dried base, C24H29NO3·HCl
 should be 98.0% to 102.0%
100.20%
Conclusion: The product complies to Enterprise standard

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s